PEG INTERFERON ALFA

Peg Interferon Alfa Adverse Events Reported to the FDA Over Time

How are Peg Interferon Alfa adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Peg Interferon Alfa, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Peg Interferon Alfa is flagged as the suspect drug causing the adverse event.

Most Common Peg Interferon Alfa Adverse Events Reported to the FDA

What are the most common Peg Interferon Alfa adverse events reported to the FDA?

Anaemia	212 (2.48%)
Nausea	133 (1.56%)
Vomiting	130 (1.52%)
Dehydration	129 (1.51%)
Syncope	118 (1.38%)
Thrombocytopenia	110 (1.29%)
Pyrexia	108 (1.26%)
Pneumonia	105 (1.23%)
Haemoglobin Decreased	99 (1.16%)
Platelet Count Decreased	88 (1.03%)
Asthenia	87 (1.02%)
	Show More
Hypokalaemia	81 (.95%)
Dyspnoea	75 (.88%)
Fatigue	69 (.81%)
Diarrhoea	68 (.8%)
Dizziness	67 (.78%)
Pancytopenia	62 (.73%)
Weight Decreased	61 (.71%)
Convulsion	60 (.7%)
Renal Failure Acute	56 (.66%)
Depression	55 (.64%)
Grand Mal Convulsion	55 (.64%)
Ascites	53 (.62%)
Neutropenia	53 (.62%)
White Blood Cell Count Decreased	52 (.61%)
Headache	47 (.55%)
Cholelithiasis	44 (.52%)
Confusional State	44 (.52%)
Retinal Detachment	42 (.49%)
Rash	41 (.48%)
Deep Vein Thrombosis	40 (.47%)
Blood Glucose Increased	39 (.46%)
Pleural Effusion	39 (.46%)
Leukopenia	38 (.44%)
Fall	37 (.43%)
Gastritis	37 (.43%)
Renal Failure	37 (.43%)
Death	36 (.42%)
Loss Of Consciousness	36 (.42%)
Malaise	36 (.42%)
Vertigo	36 (.42%)
Gastroenteritis	35 (.41%)
Guillain-barre Syndrome	34 (.4%)
Mental Status Changes	34 (.4%)
Gingival Bleeding	33 (.39%)
Appendicitis	31 (.36%)
Hypotension	31 (.36%)
Sepsis	31 (.36%)
Alanine Aminotransferase Increased	30 (.35%)
Aspartate Aminotransferase Increase...	30 (.35%)
Chest Pain	30 (.35%)
Hepatic Cirrhosis	29 (.34%)
Oedema Peripheral	29 (.34%)
Urinary Tract Infection	29 (.34%)
Cellulitis	28 (.33%)
Myocardial Infarction	28 (.33%)
Transplant Rejection	28 (.33%)
Cough	27 (.32%)
Decreased Appetite	27 (.32%)
Diabetic Ketoacidosis	27 (.32%)
General Physical Health Deteriorati...	27 (.32%)
Abdominal Pain	26 (.3%)
Haematocrit Decreased	26 (.3%)
Orthostatic Hypotension	26 (.3%)
Staphylococcal Infection	26 (.3%)
Anorexia	25 (.29%)
Cholecystitis Acute	25 (.29%)
Disorientation	25 (.29%)
Pruritus	25 (.29%)
Vision Blurred	25 (.29%)
Anxiety	24 (.28%)
Septic Shock	24 (.28%)
Atrial Fibrillation	23 (.27%)
Cholecystitis	23 (.27%)
Hepatic Encephalopathy	23 (.27%)
Hepatic Neoplasm Malignant	23 (.27%)
Hypertension	23 (.27%)
Metabolic Acidosis	23 (.27%)
Migraine	23 (.27%)
Cognitive Disorder	22 (.26%)
Neutrophil Count Decreased	22 (.26%)
Cardiac Failure	21 (.25%)
Haemorrhage	21 (.25%)
Red Blood Cell Count Decreased	21 (.25%)
Splenomegaly	21 (.25%)
Arthralgia	20 (.23%)
Facial Palsy	20 (.23%)
Hepatitis C	20 (.23%)
Hypothyroidism	20 (.23%)
Influenza Like Illness	20 (.23%)
Jaundice	20 (.23%)
Asthma	19 (.22%)
Back Pain	19 (.22%)
Epistaxis	19 (.22%)
Gastrointestinal Haemorrhage	19 (.22%)
Hyponatraemia	19 (.22%)
Pallor	19 (.22%)
Tachycardia	19 (.22%)
Chills	18 (.21%)
Myalgia	18 (.21%)
Delirium	17 (.2%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Peg Interferon Alfa, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Peg Interferon Alfa is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Peg Interferon Alfa

What are the most common Peg Interferon Alfa adverse events reported to the FDA?

Infections - Pathogen Unspecified	471 (5.52%)
Hematology Investigations	379 (4.44%)
Neurological	325 (3.81%)
Gastrointestinal Signs	320 (3.75%)
Anemias Nonhemolytic And Marrow Dep...	300 (3.51%)
Electrolyte And Fluid Balance Condi...	257 (3.01%)
Epidermal And Dermal Conditions	189 (2.21%)
Respiratory	187 (2.19%)
Hepatic And Hepatobiliary	174 (2.04%)
Bacterial Infectious	159 (1.86%)
Seizures	127 (1.49%)
	Show More
Renal Disorders	123 (1.44%)
Cardiac Arrhythmias	122 (1.43%)
White Blood Cell	118 (1.38%)
Platelet	117 (1.37%)
Body Temperature Conditions	116 (1.36%)
Gallbladder	104 (1.22%)
Injuries	104 (1.22%)
Hepatobiliary	97 (1.14%)
Lower Respiratory Tract Disorders	97 (1.14%)
Gastrointestinal Inflammatory Condi...	92 (1.08%)
Coronary Artery	86 (1.01%)
Deliria	86 (1.01%)
Gastrointestinal Motility And Defec...	85 (1%)
Headaches	81 (.95%)
Physical Examination Topics	71 (.83%)
Peripheral Neuropathies	69 (.81%)
Appetite And General Nutritional	65 (.76%)
Decreased And Nonspecific Blood Pre...	63 (.74%)
Depressed Mood Disorders	62 (.73%)
Musculoskeletal And Connective Tiss...	62 (.73%)
Peritoneal And Retroperitoneal Cond...	62 (.73%)
Central Nervous System Vascular	60 (.7%)
Mental Impairment	60 (.7%)
Psychiatric	59 (.69%)
Anxiety Disorders	58 (.68%)
Embolism And Thrombosis	58 (.68%)
Viral Infectious	58 (.68%)
Vision	58 (.68%)
Gastrointestinal Hemorrhages	57 (.67%)
Ocular Structural Change, Deposit A...	56 (.66%)
Vascular	56 (.66%)
Encephalopathies	55 (.64%)
Inner Ear And Viiith Cranial Nerve	55 (.64%)
Myocardial	55 (.64%)
Pleural	53 (.62%)
Spleen, Lymphatic And Reticulendoth...	53 (.62%)
Metabolic, Nutritional And Blood Ga...	52 (.61%)
Muscle	52 (.61%)
Cardiac And Vascular Investigations	51 (.6%)
Immune	50 (.59%)
Joint	48 (.56%)
Water, Electrolyte And Mineral	48 (.56%)
Fatal Outcomes	47 (.55%)
Thyroid Gland	45 (.53%)
Bone And Joint Injuries	42 (.49%)
Glucose Metabolism Disorders	40 (.47%)
Hepatobiliary Neoplasms Malignant A...	39 (.46%)
Dental And Gingival Conditions	38 (.44%)
Lifestyle Issues	36 (.42%)
Personality Disorders	36 (.42%)
Medication Errors	35 (.41%)
Heart Failures	34 (.4%)
Renal And Urinary Tract Investigati...	34 (.4%)
Retina, Choroid And Vitreous Hemorr...	34 (.4%)
Upper Respiratory Tract Disorders	34 (.4%)
Cranial Nerve Disorders	33 (.39%)
Bronchial Disorders	32 (.37%)
Chemical Injury And Poisoning	32 (.37%)
Acid-base	31 (.36%)
Movement Disorders	31 (.36%)
Ocular Infections, Irritations And ...	31 (.36%)
Suicidal And Self-injurious Behavio...	31 (.36%)
Urinary Tract Signs	31 (.36%)
Diabetic Complications	30 (.35%)
Therapeutic And Nontherapeutic Effe...	30 (.35%)
Skin Appendage Conditions	28 (.33%)
Pericardial	27 (.32%)
Exocrine Pancreas Conditions	26 (.3%)
Gastrointestinal Vascular Condition...	26 (.3%)
Microbiology And Serology	26 (.3%)
Cardiac Disorder Signs	25 (.29%)
Mood Disorders	25 (.29%)
Pulmonary Vascular	25 (.29%)
Vascular Hemorrhagic	25 (.29%)
Cardiac Valve	24 (.28%)
Schizophrenia And Other Psychotic	24 (.28%)
Vascular Hypertensive	24 (.28%)
Fungal Infectious	23 (.27%)
Sleep Disorders	23 (.27%)
Bile Duct	22 (.26%)
Disturbances In Thinking	22 (.26%)
Menstrual Cycle And Uterine Bleedin...	22 (.26%)
Enzyme	21 (.25%)
Immunology And Allergy	21 (.25%)
Mycobacterial Infectious	21 (.25%)
Protein And Chemistry Analyses	21 (.25%)
Hearing	20 (.23%)
Procedural And Device Related Injur...	19 (.22%)
Administration Site Reactions	18 (.21%)
Respiratory And Mediastinal Neoplas...	18 (.21%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Peg Interferon Alfa, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Peg Interferon Alfa is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.